



August 1, 2019

Re: Clinical Criteria and prior authorization updates for specialty pharmacy are available

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Nevada (Anthem), is writing to inform you of the following updates to the AIM Specialty Health® (AIM) Clinical Criteria and prior authorization requirements. AIM is a separate company.

Below are Clinical Criteria and prior authorization updates were endorsed at the May 17, 2019 Clinical Criteria meeting. To access and download a copy of the current guidelines, go to: <https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html>

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Revised Clinical Criteria effective June 10, 2019

The following new clinical criteria were revised to expand medical necessity indications or criteria. The table below will assist you in identifying the new document number for the clinical criteria that corresponds with the previous Clinical or Coverage Guideline.

Clinical or Coverage Guideline	Clinical Criteria	Clinical Criteria Name	Drug(s)	HCPCS or CPT Code(s)
CG-DRUG-106	ING-CC-0092	Adcetris (brentuximab)	Adcetris	J9042
CG-DRUG-38	ING-CC-0094	Alimta (pemetrexed)	Alimta	J9305
CG-DRUG-42	ING-CC-0096	Asparagine Specific Enzymes	Erwinaze, Asparaginase, Oncaspar	J9019, J9020, J9266
CG-DRUG-63	ING-CC-0104	Leucovorin and Levoleucovorin agents	Fusilev, Khapzory	J0641, C9043, J3490
CG-DRUG-66	ING-CC-0105	Vectibix (panitumumab)	Vectibix	J9303
CG-DRUG-72	ING-CC-0110	Perjeta (pertuzumab)	Perjeta	J9306
CG-DRUG-96	ING-CC-0115	Kadcyla (ado-trastuzumab)	Kadcyla	J9354
CG-DRUG-98	ING-CC-0116	Bendamustine agents	Bendeka, Treanda, Belrapzo	J9034, J9033, C9042, J9999
DRUG.00046	ING-CC-0119	Yervoy (ipilimumab)	Yervoy	J9228
DRUG.00053	ING-CC-0120	Kyprolis (carfilzomib)	Kyprolis	J9047

DRUG.00063	ING-CC-0122	Arzerra (ofatumumab)	Arzerra	J9302
DRUG.00067	ING-CC-0123	Cyramza (ramucirumab)	Cyramza	J9308
DRUG.00071	ING-CC-0124	Keytruda (pembrolizumab)	Keytruda	J9271
DRUG.00075	ING-CC-0125	Opdivo (nivolumab)	Opdivo	J9299
DRUG.00107	ING-CC-0129	Bavencio (avelumab)	Bavencio	J9023

Revised Clinical Criteria effective September 1, 2019

The following new clinical criteria were reviewed with no significant change to the medical necessity indications or criteria. The table below will assist you in identifying the new document number for the clinical criteria that corresponds with the previous Clinical or Coverage Guideline.

Clinical or Coverage Guideline	Clinical Criteria	Clinical Criteria Name	Drug(s)	HCPCS or CPT Code(s)
CG-DRUG-100	ING-CC-0085	Actimmune (interferon gamma-1B)	Actimmune	J9216
CG-DRUG-101	ING-CC-0090	Ixempra (ixabepilone)	Ixempra	J9207
CG-DRUG-102	ING-CC-0091	Lartruvo (olaratumab)	Lartruvo	J9285
CG-DRUG-49	ING-CC-0098	Doxorubicin Hydrochloride Liposome	Lipodox, Doxorubicin hydrochloride liposomal, Doxil	Q2049, Q2050
CG-DRUG-50	ING-CC-0099	Abraxane (paclitaxel protein-bound)	Abraxane	J9264
CG-DRUG-51	ING-CC-0100	Istodax (romidepsin)	Istodax	J9315
CG-DRUG-62	ING-CC-0103	Faslodex (fulvestrant)	Faslodex	J9395
CG-DRUG-67	ING-CC-0106	Erbix (cetuximab)	Erbix	J9055
CG-DRUG-68	ING-CC-0107	Bevacizumab agents (Avastin, Mvasi)	Avastin, Mvasi	J9035, Q5107
CG-DRUG-70	ING-CC-0108	Halaven (eribulin)	Halaven	J9179
CG-DRUG-71	ING-CC-0109	Zaltrap (ziv-aflibercept)	Zaltrap	J9400
CG-DRUG-75	ING-CC-0111	Nplate (romiplostim)	Nplate	J2796
CG-DRUG-77	ING-CC-0112	Xofigo (Radium Ra 223 Dichloride)	Xofigo	A9606, 79101
CG-DRUG-80	ING-CC-0114	Jevtana (cabazitaxel)	Jevtana	J9043
CG-DRUG-99	ING-CC-0117	Empliciti (elotuzumab)	Empliciti	J9176
CG-THER-RAD-03	ING-CC-0118	Radioimmunotherapy: Zevalin; azedra; Lutathera	Zevalin, Azedra, Lutathera	79403, A9543, 79101, A9699, C9408, A9513
DRUG.00062	ING-CC-0121	Gazyva (obinutuzumab)	Gazyva	J9301

DRUG.00076	ING-CC-0126	Blinicyto (blinatumomab)	Blinicyto	J9039
DRUG.00082	ING-CC-0127	Darzalex (daratumumab)	Darzalex	J9145
DRUG.00088	ING-CC-0128	Tecentriq (atezolizumab)	Tecentriq	J9022
DRUG.00109	ING-CC-0130	Imfinzi (durvalumab)	Imfinzi	J9173
CG-DRUG-113	ING-CC-0131	Besponsa (inotuzumab ozogamicin)	Besponsa	J9229
DRUG.00112	ING-CC-0132	Mylotarg (gemtuzumab ozogamicin)	Mylotarg	J9203
DRUG.00118	ING-CC-0133	Aliqopa (copanlisib)	Aliqopa	J9057
MED.00106	ING-CC-0134	Provenge (Sipuleucel- T)	Provenge	Q2043
CG-MED-67	ING-CC-0135	Melanoma Vaccines	Imlygic	J9325, J3590
CG-DRUG-53	ING-CC-0136	Drug dosage, frequency, and route of administration	N/A	N/A
CG-DRUG-01	ING-CC-0141	Off-Label Drug and Approved Orphan Drug Use	N/A	N/A

Revised Clinical Criteria effective November 1, 2019

The following current and new clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

- ING-CC-0048 Spinraza (nusinersen)
- ING-CC-0002 Colony Stimulating Factor Agents
- ING-CC-0113 Sylvant (siltuximab) [previously CG-DRUG-79]

New Clinical Criteria effective November 1, 2019

The following clinical criteria are new.

- ING-CC-0137 Cablivi (caplacizumab-yhdp)
- ING-CC-0138 Asparlas (calaspargase pegol-mknl)
- ING-CC-0139 Evenity (romosozumab-aqqg)
- ING-CC-0140 Zulresso (brexanolone)

Expanded specialty pharmacy prior authorization list

Effective for dates of service on and after November 1, 2019, the following non-oncology specialty pharmacy codes from current clinical criteria will be included in our prior authorization review process.

Please note, inclusion of NDC code on your claim will shorten the claim processing time of drugs billed with a Not Otherwise Classified (NOC) code.

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Clinical Criteria	HCPCS or CPT Code(s)	NDC Code(s)	Drug
ING-CC-0050	J3490 J3590	00074-2042-01 00074-2042-02	Skyrizi™

We value and appreciate you as our partner in providing quality care, and appreciate your continued participation in our network.

Sincerely,



Allen Marino, M.D.
Medical Director
Anthem Blue Cross and Blue Shield